Owlstone Medical

Owlstone Medical is the recognized leader in breath-based VOC biomarker research and diagnostic test development. Its core Breath Biopsy® platform enables the reliable collection and analysis of breath samples, offering a completely non-invasive window into systemic health for early disease detection and treatment monitoring. The company operates a dual business model, providing research products and services to partners while advancing its own pipeline of diagnostic tests, supported by significant non-dilutive funding and venture investment. Its vision is to become the global standard in breath analysis, with active programs targeting multi-cancer early detection and specific conditions like cystic fibrosis.

Breath Biopsy® platform for non-invasive collection and analysis of volatile organic compounds (VOCs) and other analytes in exhaled breath. Includes proprietary EVOC® Probes for targeted pathway assessment, breath sampling devices, and advanced analytical methods (FAIMS, GC-MS).

Owlstone is a recognized leader in breath VOC analysis, but faces competition from other breath diagnostic startups (e.g., for specific conditions like asthma or gastric cancer) and the broader, well-funded liquid biopsy sector for cancer detection. Its integrated platform and EVOC® Probe technology provide defensible differentiation.